跳至主要内容
临床试验/IRCT20210211050323N2
IRCT20210211050323N2招募中2 期

Clinical trial to evaluate the effect of rosuvastatin adjuvant therapy on Sirtuin1 gene expression in the treatment of multiple sclerosis

Hamedan University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 years 至 70 years(—)
性别
All

入选标准

  • Definitive diagnosis of multiple sclerosis by a neurologist
  • Radiographic findings of magnetic resonance imaging ( MRI ) consistent with the clinical diagnosis of multiple sclerosis
  • No other concomitant inflammatory disease
  • Bad cholesterol levels (low-density lipoprotein) less than 130 mg / dL
  • No pregnancy and lactation
  • Do not take medications other than standard treatments for multiple sclerosis that alter the levels of the factors under consideration.
  • Do not use any combination with antioxidant effects in the past month.

排除标准

  • Existing evidence based on increased patient disability
  • Consumption of any combination or drug with antioxidant effects except prescription drugs
  • Existence of any cognitive or behavioral disorders that lead to the patient not cooperating.

研究者

相似试验